2015 American Transplant Congress
Antibody Response Following Influenza Vaccination in Renal Transplant Recipients
Indiana University School of Medicne-IU Health, Indianapolis, IN.
Purpose: Following the recommended consensus guidelines of ATC for vaccination, at our institution we recommend annual vaccination for influenza + H1N1 (Flu) for renal transplant…2015 American Transplant Congress
Clinical Outcome of Patients With De Novo C1q Binding Donor-Specific HLA Antibodies After Renal Transplantation
A. Not all de novo donor-specific HLA antibodies (dnDSA) are causing immediate graft loss. The importance of complement-binding DSA was recently shown with a commercial…2015 American Transplant Congress
Deceased Donor HLA Antibody Incompatible Renal Transplantation Without Antibody Removal: High Incidence of Acute Rejection Reduced By T-Cell Depleting Induction Therapy
Aims: Screening for HLA-specific antibodies (Ab) is routine for patients on kidney transplant waiting lists, and HLA antigens to which a patient has detectable Ab…2015 American Transplant Congress
Impact of Donor Specific Antibodies in the Older Kidney Transplant Recipient
Houston Methodist Hospital, Houston.
Recent evidence suggests that renal transplant recipients (RTR) with both rejection and donor specific antibodies (DSA) are at high risk of graft loss. Concurrently, the…2015 American Transplant Congress
Cognate Events in Antibody- Vs. T Cell-Mediated Rejection: A Molecular Perspective
AIM: The cognate event in antibody-mediated rejection (ABMR) is NK cell FcR engagement; T cell mediated rejection (TCMR) uses TCR engagement. Understanding the molecular changes…2015 American Transplant Congress
Early Antibody Mediated Rejection in HLA Antibody Incompatible Kidney Transplantation – A Treatable Condition Without Heavy Induction Immunosuppression
Transplantation across preformed donor specific HLA antibodies (DSA) not only carries a risk of early acute antibody mediated rejection (AMR) and graft loss, but also…2015 American Transplant Congress
Distinct Clinical Relevance of BAFF Expression Within the Kidney Graft and Soluble BAFF Serum Levels Indicate Confined Alloimmune Responses Disconnected from the Periphery
As soluble B-cell activating factor (BAFF) serum levels (sBAFF) may not reflect BAFF concentrations within the graft, what could be related to the inconsistencies in…2015 American Transplant Congress
Long Term Outcomes of Tocilizumab Therapy for DSA+ Antibody Mediated Rejection (ABMR) Resistant to IVIG + Rituxan (I+R) Treatment
Intro: Limited options are available for treatment of ABMR in highly-HLA sensitized patients (HS). Treatment options include I+R, PLEX+I+/- R, C5-inhibitor & bortezomib. Approximately 25%…2015 American Transplant Congress
Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?
HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.
Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which…2015 American Transplant Congress
Clinical and Immunologic Risk Factors Associated With Donor-Specific Antibody (DSA) Formation Following Renal Transplantation
Background: De novo DSA formation is emerging as an important risk factor for adverse graft outcomes following renal transplantation. Specific pretransplant risk factors for DSA…
- « Previous Page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- …
- 47
- Next Page »